Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the rating you have given Submit Feedback

Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA).The drug,

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

Regeneron (REGN) and Sanofi's (SNY) asthma therapy Dupixent receives FDA approval for label expansion in treating certain patients with COPD. Read more here.